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Background: Autophagy is an intracellular lysosomal
degradation pathway implicated in many diseases, but
there are currently no specific autophagy inhibitors.
Results: Small molecule inhibition of ULK1, the
upstream autophagy initiating kinase, blocks autophago-
some initiation and maturation.
Conclusion: ULK1 plays a role in autophagosome matu-
ration as well as initiation.
Significance: ULK1 can be targeted to block autophagy
for disease therapy.
Autophagy is a cell-protective and degradative process that
recycles damaged and long-lived cellular components. Cancer
cells are thought to take advantage of autophagy to help them to
cope with the stress of tumorigenesis; thus targeting autophagy
is an attractive therapeutic approach. However, there are cur-
rently no specific inhibitors of autophagy. ULK1, a serine/thre-
onine protein kinase, is essential for the initial stages of
autophagy, and here we report that two compounds, MRT67307
and MRT68921, potently inhibit ULK1 and ULK2 in vitro and
block autophagy in cells. Using a drug-resistant ULK1 mutant,
we show that the autophagy-inhibiting capacity of the com-
pounds is specifically through ULK1. ULK1 inhibition results in
accumulation of stalled early autophagosomal structures, indi-
cating a role for ULK1 in the maturation of autophagosomes as
well as initiation.
Macroautophagy, called autophagy in this instance, is a
membrane-driven process that traffics intracellular compo-
nents to the lysosome for recycling (1). It is essentially a cell
survival mechanism and is up-regulated under conditions of
stress, allowing cells to supply building blocks and energy to
maintain function during periods of starvation. Autophagy also
eliminates impaired or foreign components that if left to persist
could cause damage. Due to these functions, autophagy has
been linked to many diseases from neurodegeneration to can-
cer (2). It is therefore an attractive therapeutic target, especially
in cancer where it acts as a survival mechanism allowing the
tumor to cope with an increased metabolic demand and dam-
age caused by chemotherapeutics (3, 4). Hence, autophagy inhi-
bition is thought to be a viable treatment approach. However, to
date there are no specific small molecule autophagy inhibitors,
and this has hampered validation of autophagy as a potential
target in cancer. Hydroxychloroquine has entered clinical trials
as an autophagy inhibitor (5–11), but it is far from specific given
that it disrupts lysosomal function. The lysosome is the end
point of autophagy as well as most other intracellular transport
pathways including endocytosis.
The most understood pathway of autophagy activation
occurs upon inhibition of mTOR,2 either by amino acid with-
drawal or by a direct pharmacological block. This leads to acti-
vation of the ULK1 protein kinase complex followed by the
VPS34 lipid kinase complex (12–15). This in turn leads to the
recruitment of a unique ubiquitin-like conjugation system
resulting in the conjugation of LC3, and its family members, to
the lipid phosphatidylethanolamine in the forming autophago-
some, or phagophore. This lipidated form of LC3, termed LC3-
II, is thought to drive elongation and cargo incorporation into
the autophagosome (16). Thus there are many potential targets
to inhibit autophagy. Kinase inhibitors have proved successful
in the clinic, making ULK1 and VPS34 attractive candidates for
inhibition. Studies about specific VPS34 inhibitors have
recently been published, and these substances do indeed inhibit
autophagy (17–19). However, VPS34 is also essential for sorting
in the endocytic pathway, meaning that like hydroxychloro-
quine, VPS34 inhibition also affects endocytosis and lysosomal
turnover in general. ULK1, on the other hand, is believed to be
specific for autophagy, although other roles cannot be ruled out
at this stage (20). We therefore set out to identify compounds
that could inhibit ULK1 activity, not only to act as tool reagents
to aid research but importantly to provide a proof-of-principle
that targeting ULK1 could block autophagy.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—MRT compounds were synthe-
sized as described (21). AZD8055 was from Selleck Chemicals,
and bafilomycin A1 was from Enzo Life Sciences. Rabbit anti-
ULK1, anti-ATG5, and anti-ATG13 were from Sigma. Rabbit
anti-phospho-Ser-757 ULK was from Cell Signaling Technol-
ogy, and rabbit anti-phospho-Ser-318 ATG13 was from
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Abnova. Mouse anti -tubulin was from Merck-Millipore.
Mouse anti-LC3 for immunofluorescence was from MBL Inter-
national, and sheep anti-LC3, used for immunoblotting, was
generated by the Division of Signal Transduction Therapy, Uni-
versity of Dundee, from recombinant full-length human GST-
LC3b and affinity-purified.
Recombinant DNA—Procedures were performed using
standard protocols and mutagenesis was performed using
QuikChange site-directed mutagenesis (Stratagene). Con-
structs are described and available on the MRC-PPU Reagents
website.
Cell Culture—Immortalized wild-type mouse embryonic
fibroblasts (MEFs) have been described previously (22). LKB1
MEFs were a kind gift from Tomi Mäkelä (University of Hel-
sinki, Finland) and have been described previously (23).
ULK1/2 double knock-out MEFs were a kind gift from Craig
Thompson (Memorial Sloan-Kettering Cancer Center) and
have been described previously (24). TBK1/IKK knock-out
and matched MEFs were a kind gift from Shizuo Akira (Osaka
University, Japan) and have been described previously (25).
MEFs and 293T cells were grown in DMEM, supplemented
with 10% fetal bovine serum and penicillin/streptomycin, and
cultured at 37 °C, 5% CO2. For induction of autophagy, cells
were typically grown to 75% confluency, washed twice, and
incubated in Earle’s balanced salt solution (EBSS) for 1 h (or
complete medium as a control) unless indicated. MRT67307
(10 M), MRT68921 (1 M), AZD8055 (1 M), or bafilomycin
A1 (50 nM) was included where indicated. Transfection and
transduction were as described (15).
Cell Lysis and Immunoprecipitation—Cell lysis and immuno-
precipitation were carried out as described (15). Immunoblots
were quantified by densitometry, using ImageJ.
Immunofluorescence—Immunofluorescence was carried out
as described (26). Slides were visualized on a Nikon TiS inverted
microscope, and images were processed using NIS Elements
(Nikon) and Adobe Photoshop.
Live Cell Microscopy—Cells were washed and incubated in
phenol red-free medium and imaged on a Nikon TiE inverted
microscope with an Okolab environmental chamber at 37 °C,
5% CO2. Images were obtained and processed using NIS Ele-
ments (Nikon).
Kinase Assays—Initial ULK1 kinase assays were performed
with GST-ULK1, produced in Sf9 cells, which is described on
the MRC-PPU Reagents website. For other experiments,
recombinant GST-ULK1 (wild type, kinase-dead (K46I), and
M92T and M92Q) was expressed in 293T cells, purified, and
eluted from a glutathione-Sepharose column. Kinase assays
were carried out in 50 mM Tris-HCl, pH 7.4, 10 mM magnesium
acetate, 0.1 mM EGTA, and 0.1% -mercaptoethanol, contain-
ing 30 M cold ATP, and 0.5 Ci of [-32P]ATP for 5 min at
25 °C. Prior to ATP addition, reaction mixes were prewarmed
to 25 °C for 5 min. Reactions were stopped by the addition of
sample buffer, followed by SDS-PAGE, transfer to nitrocellu-
lose, and analysis by autoradiography and immunoblot. For
IC50 curve measurements, kinase assays were performed as
described (27), using myelin basic protein (Sigma) as a sub-
strate. Kinase profiling was as described (28), performed by the
International Centre for Kinase Profiling.
Statistical Analysis—Experiments were carried out a mini-
mum of three times, and error bars represent S.E. Significance
in related samples was determined by paired student’s t test. A
p value of 0.05 or less was deemed significant.
RESULTS AND DISCUSSION
In vitro screening of known kinase inhibitors led to the dis-
covery that the TBK1 inhibitor, MRT67307 (29), also targeted
ULK1 and ULK2 with high potency (IC50 values of 45 and 38
nM, respectively, Fig. 1A). It is of no surprise that a compound
would target both ULK1 and ULK2, given the high degree of
similarity between the kinase domains; it is also desirable given
the degree of redundancy observed in knock-out mouse models
(20). To find more potent inhibitors, we re-analyzed a closely
related series of analogues generated during the original TBK1
screen. This led to the discovery of MRT68921 as the most
potent inhibitor of both ULK1 and ULK2, with greater than a
15-fold reduction in the IC50 for ULK1 (2.9 nM) and greater
than a 30-fold reduction for ULK2 (1.1 nM) (Fig. 1A). To see
whether in vitro activity of the compounds could translate to
inhibition in cells, we treated MEFs with either MRT67307 or
MRT68921, in combination with amino acid withdrawal, to
inhibit mTOR and activate ULK1. Bafilomycin A1 was also
included to inhibit lysosomal turnover and enable autophagic
flux measurement (30) (Fig. 1B). Loss of mTOR-mediated
ULK1 phosphorylation occurred upon incubation of cells in
EBSS, and this was not prevented by treatment with either of
the MRT compounds. ATG13 phosphorylation at serine 318
was used as a measure of ULK1 activity (31), and this correlated
well with EBSS treatment and loss of the ULK1 mTOR phos-
phorylation, showing greater than a 5-fold increase over basal
levels (Fig. 1B). 10 M MRT67307 was sufficient to reduce
phospho-ATG13 to control levels, and in line with the in vitro
IC50 values, 10-fold less MRT68921 (1 M) resulted in a similar
reduction. Therefore, these compounds can reduce ULK1
activity in cells. Importantly, these compounds also block
autophagy as indicated by LC3-II levels. Basal autophagy was
low under the experimental conditions used; however, EBSS
treatment resulted in a 5-fold increase in bafilomycin-sensitive
LC3-II levels, indicating strong mTOR-dependent autophagy
induction. Both compounds blocked any bafilomycin-induced
increase, demonstrating inhibition of autophagic flux. Both
compounds behaved similarly, and although there was no
LC3-II flux, a small 2-fold increase in LC3-II levels was
observed.
ULK1 is part of a multi-protein complex, and at least two of
these proteins, ATG13 and FIP200, are required for maximal
ULK activity (13–15); it is possible that the MRT compounds
inhibit ULK by disrupting these interactions. To look at this, we
stably expressed FLAG-tagged ULK1 in ULK1 and ULK2 dou-
ble-knock-out (dKO) cells and immunoprecipitated ULK in the
presence or absence of autophagy-inducing conditions. As can
be seen in Fig. 1C, the presence of inhibitor did not reduce the
amounts of ATG13 and FIP200 co-precipitating with ULK1,
but did reduce the level of phosphorylated ATG13 in this com-
plex. To further assess autophagy, we looked at endogenous
LC3 by immunofluorescence (Fig. 1D). Under control condi-
tions, MRT68921 caused a slight reduction in basal LC3 puncta,
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indicating that the compound can block basal autophagy. How-
ever, the changes were not statistically significant, which could
be due to low basal level of autophagy during the treatment. In
contrast and as with the Western blot data, EBSS caused a large
increase in bafilomycin-sensitive LC3 puncta accumulation.
Likewise, this was blocked by both MRT compounds (although
only MRT68921 is shown in Fig. 1D), confirming that these
compounds do indeed block autophagy in cells. Also, like the
Western blot data (Fig. 1B), a small 2-fold increase in distinct
LC3 puncta was observed with the inhibitors, which may rep-
resent stalled phagophores (see below).
Both MRT compounds inhibit ULK1 in vitro and in cells, and
also block autophagy. However, they could be targeting
autophagy through another kinase. The in vitro kinase profiling
of MRT67307 revealed that it is a relatively specific kinase
inhibitor, targeting TBK1/IKK but also hitting the AMPK-re-
lated kinases (33). To assess the specificity of MRT68921, we
profiled the inhibitor at 1 M against a broad panel of 80 protein
kinases representing all areas of the human kinome (Fig. 2A). As
with MRT67307, MRT68921 was relatively specific, but still
inhibited a number of kinases by over 80% (Fig. 2A, dark shaded
bars). Most notably, TBK1/IKK and the AMPK-related
kinases were still targeted. TBK1 and AMPK have been impli-
cated in autophagy (34 – 40), so it was important to rule these
out as autophagy-inhibiting targets of MRT68921. To analyze
the role of TBK1, we took knock-out MEFs and asked whether
autophagy could still be induced and inhibited by MRT68921
(Fig. 2B). To induce autophagy, we utilized the mTOR inhibitor
FIGURE 1. MRT67307 and MRT68921 inhibit ULK and block autophagy in cells. A, summary of MRT67307 and 68921 structures and in vitro ULK1 and ULK2
IC50 values. B, MEF cells were incubated in EBSS for 1 h in the presence or absence of 10 M MRT67307, 1 M MRT68921, or 50 nM bafilomycin A1, followed by
lysis and immunoblotting with the indicated antibodies (* indicates nonspecific staining). Quantitation of phospho-serine 318 (pS318) of ATG13, normalized to
total ATG13, is shown below next to quantitation of LC3-II levels, normalized to tubulin. pS757, phospho-Ser-757; DMSO, dimethyl sulfoxide; ctrl, control. C,
representative blot of a FLAG immunoprecipitation from ULK1/2 double knock-out MEFs (ULK dKO) expressing FLAG-ULK1. D, representative micrographs of
endogenous LC3 immunofluorescence in MEFs incubated in complete medium (control) or EBSS for 1 h in the presence or absence of 1 M MRT68921 and 50
nM bafilomycin A1. Quantitation of LC3 puncta is shown on the right. All quantitation represent means  S.E. from at least three independent experiments. *,
p  0.05. Scale bar, 10 m. n/s, not significant.
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AZD8055 (41) and in TBK1-containing cells, we found a large
increase in LC3-II flux, which was inhibited by MRT68921. In
TBK1 knock-out cells, the pattern of LC3-II accumulation was
almost identical, indicating that TBK1 is not essential for
mTOR-mediated autophagic flux and is not the autophagy-in-
hibiting target of MRT68921. Of course we do not rule out the
involvement of TBK1 in more specific forms of autophagy such
as basal autophagy or xenophagy. However, this result high-
lights the caution that is needed when using TBK1 inhibitors to
validate a role for TBK1 in autophagy.
To analyze AMPK-related kinase involvement, we took
advantage of the fact that these kinases, with the exception of
AMPK (which can also be activated by CaMKK2), require
LKB1-mediated phosphorylation for activation (42). Using
LKB1 knock-out MEFs, we found that LC3 flux was comparable
with matched, wild-type MEFs and was inhibited to the same
extent with MRT68921 (Fig. 2C). Therefore, these kinases are
not the target of MRT68921 in blocking autophagy. Interest-
ingly, LC3 flux was slightly higher under basal and autophagy-
inducing conditions in the LKB1 knock-out MEFs, which is
similar to that seen in AMPK knock-out cells (36). This sup-
ports the idea that AMPK, or one of the related kinases,
although not essential for autophagy, does play a regulatory
role.
Both the MRT compounds are competitive ATP-binding site
inhibitors and may inhibit autophagy through other kinases, or
even non-kinase ATP-binding proteins. To rule this out and
confirm ULK1 as the target, we generated a drug-resistant
ULK1 mutant. The gatekeeper residue is a bulky hydrophobic
amino acid present at the base of the ATP-binding pocket in all
typical protein kinases. When this residue is mutated, it can
change the ATP binding properties of the kinase. To identify
residues that might result in loss of inhibitor binding, but retain
ATP binding, we mutated the gatekeeper residue of ULK1
(methionine 92) to various amino acids. Mutation to alanine or
glycine resulted in loss of kinase activity, but a change to thre-
onine or glutamine resulted in an ULK1 construct that retained
in vitro activity in a simple autophosphorylation kinase assay
(Fig. 3A). Satisfyingly, mutation of methionine 92 to threonine
(M92T) allowed ULK1 to retain kinase activity in the presence
of MRT67307, at a concentration that inhibited WT and the
glutamine mutant. To analyze the resistance of ULK1 M92T to
the MRT compounds in greater detail, we characterized the
IC50 for this mutant and found over a 70-fold decrease in sen-
sitivity, confirming the drug resistance (Fig. 3B).
We next confirmed that the M92T mutant could rescue the
MRT68921-mediated autophagy inhibition. For this, either
WT or M92T FLAG-ULK1 was stably expressed in ULK1/2
FIGURE 2. Kinase selectivity of MRT68921. A, activity of 80 recombinant kinases measured in the presence of 1 M MRT68921. Data represent percentage of
activity remaining relative to activity in the absence of inhibitor. Darker shaded bars to the right indicate kinases that were inhibited by over 80%. B, TBK1
knock-out (KO) and matched wild-type (WT) MEFs were incubated with/without 1 M AZD8055 in the presence or absence of 50 nM bafilomycin (baf.) and 1 M
MRT68921. A representative immunoblot is shown with quantitation of LC3-II levels normalized to tubulin above. ctrl, control. C, similar to panel B, but LKB1
knock-out and matched wild-type MEFs were used. All quantitations are from three independent experiments  S.E. *, p  0.05, ***, p  0.001.
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dKO MEFs (Fig. 3C). Re-expression of WT or M92T ULK1
restored ATG13 phosphorylation and autophagy (as observed
by LC3-II flux), caused by the loss of endogenous ULK1 and
ULK2. In these cells, it appears that ULK1 is sufficient to rescue
autophagy, highlighting the redundancy of ULK2. Importantly,
MRT68921 was able to inhibit the WT-restored ATG13 phos-
phorylation and autophagy similarly to cells expressing endog-
enous ULK1 (compare Fig. 1B with 3C). However, in cells
expressing a similar level of M92T ULK1, MRT68921 failed to
reduce either ATG13 phosphorylation or LC3 flux (Fig. 3C).
This indicates that MRT68921 is indeed blocking autophagy
through ULK1 kinase inhibition. To our knowledge, this is the
first example of specifically inhibiting ULK1 with a small mol-
ecule to disrupt autophagy.
To confirm inhibition is through ULK1, we used the ULK1
rescue MEFs to analyze LC3 immunofluorescence (Fig. 3D).
Cells expressing both WT and M92T ULK1 displayed a com-
parable increase in the number of bafilomycin-sensitive LC3
puncta in response to EBSS treatment. Similarly, the LC3
puncta flux was blocked by MRT68921 treatment only in the
WT ULK1-expressing cells, not the M92T ULK1 cells, confirm-
ing the MRT compound blocks autophagy through ULK1 inhi-
bition. As with the immunofluorescence analysis in cells endog-
enously expressing ULK (Fig. 1D), we did see a small increase in
the formation of distinct and bright LC3 puncta upon
MRT68921 treatment in the WT-expressing cells, and given
that no LC3 flux was observed, these structures could possibly
represent stalled phagophores or immature autophagosomes.
FIGURE 3. MRT68921 specifically blocks autophagic flux through ULK1 inhibition. A, in vitro ULK1 autophosphorylation kinase assay in the presence of 1
M MRT67307 with GST-tagged wild-type (WT), kinase-dead (KD (K46I)), and M92T (T) and M92Q (Q) ULK1. B, in vitro IC50 plot with GST-tagged WT and M92T
ULK1 in the presence of MRT68921. C, ULK1/2 dKO MEFs, stably expressing FLAG-tagged WT or M92T ULK1, were treated with EBSS for 1 h in the presence or
absence of 1 M MRT68921 and 50 nM bafilomycin (baf). Lysates were subjected to immunoblotting with the indicated antibodies. Quantitation of LC3-II levels,
normalized to tubulin, is shown on the right. pS318, phospho-serine 318. D, endogenous LC3 immunofluorescence in ULK dKO MEFs rescued with the indicated
FLAG-tagged ULK1 construct. Cells were incubated in complete medium (control) or EBSS for 1 h in the presence or absence of 1 M MRT68921 and 50 nM
bafilomycin. Quantitation of LC3 puncta is shown on the right. All quantitations represent means  S.E. from at least three independent experiments. *, p 
0.05. Scale bar, 10 m. n/s, not significant.
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These bright puncta were not readily observed under control
conditions with inhibitor, indicating that stimulated autophagy
differs somewhat from basal autophagy or that the equivalent
puncta that accumulate are smaller and harder to distinguish
from the background staining. To gain further insight into
these aberrant structures, we carried out live cell microscopy in
GFP-LC3-expressing ULK1 rescue cells (see supplemental
Movies 1 and 2). Incubation of both WT-expressing and M92T
ULK1-expressing cells in EBSS resulted in rapid formation of
GFP-LC3 autophagosomes after as little as 15 min. In contrast,
in WT but not M92T cells, MRT68921 treatment delayed the
formation of GFP-LC3 structures, which only started to accu-
mulate following 30 min of treatment. Additionally, these
structures appeared brighter and morphologically distinct to
those formed in the untreated WT cells (or treated/untreated
M92T ULK1 cells). The reader is encouraged to watch the mov-
ies, but representative images are shown in Fig. 4A. The distinct
appearance, timing, and lack of flux of the inhibitor-induced
LC3 structures suggested that they are not regular autophago-
somes. We hypothesized that ULK1 inhibition primarily blocks
autophagy induction; however, some residual ULK activity
remains to allow autophagosome initiation but not maturation.
FIGURE 4. ULK inhibition also disrupts autophagosome maturation. A, ULK1 rescue MEFs stably expressing GFP-LC3 were washed and placed in complete
medium or EBSS with/without 1 M MRT68921, and images were taken every 30 s for 90 min. Representative images are shown from EBSS-treated samples,
derived from supplemental Movie 1 (WT ULK, top panels) or supplemental Movie 2 (M92T ULK1, bottom panels). DMSO, dimethyl sulfoxide. B, MEF cells were
incubated in EBSS for 1 h with/without 1 M MRT68921 followed by fixing and staining with antibodies to LC3 (red) or ULK1 (green). Quantitation of the degree
of co-localization is shown to the right. C, cells, treated as in panel B, were stained for LC3 (red) and ATG5 (green). All quantitations represent means  S.E. from
at least three independent experiments. *, p  0.05. Scale bars, 10 m.
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To analyze this further, we co-stained cells for LC3 and the
phagophore markers ULK1 and ATG5 (Fig. 4, B and C). We
found that the majority of the inhibitor-induced LC3 struc-
tures, over 70%, contained ULK1 and ATG5, which is in con-
trast to structures found in the absence of inhibitor that showed
less than a third co-localizing with ULK1 or ATG5. Addition-
ally, inhibitor treatment did not appear to reduce the number of
ULK1 or ATG5 puncta forming upon autophagy stimulation.
Firstly, this suggests that ULK activity is not essential for its
recruitment to autophagosomal structures (a similar observa-
tion has been made with kinase-dead ULK1 constructs (43)).
Secondly, given that the LC3 structures contain ULK1 and
ATG5, both phagophore markers (44, 45), this suggests that
ULK1 plays a role in phagophore maturation into complete
autophagosomes. This is not an unreasonable proposal as a
similar phenomenon has been observed in yeast, whereby
expression of a kinase-dead form of Atg1 (yeast ULK) did
indeed block autophagy, but also resulted in increased recruit-
ment of Atg8 (yeast LC3 homolog) and Atg17 to the pre-au-
tophagosomal structure (46). Additionally, in mammalian cells,
dissociation of ULK1 from the omegasome precedes autopha-
gosome maturation (47). Our data fit well with these observa-
tions, suggesting a function for Atg1/ULK1 activity in disas-
sembly of the pre-autophagosomal structure/phagophore to
allow autophagosome maturation. However, further work in
characterizing these structures is needed to clarify this. We
therefore suggest that ULK regulates autophagy through at
least two mechanisms: (i) regulation of the VPS34 complex, by
AMBRA1/Beclin1 phosphorylation, upstream of LC3 conjuga-
tion (12, 32); and (ii) controlling maturation of the phagophore
and transition to the mature autophagosome, downstream of
LC3 conjugation.
In summary, we have shown that MRT67307, and especially
MRT68921, potently inhibit ULK1 and ULK2 in vitro and
ULK1 in cells. Importantly, this was sufficient to block
autophagic flux. We demonstrated specificity in the autophagy
block through the generation of the drug-resistant M92T ULK1
mutant. Although it might be expected that pharmacologically
inhibiting ULK1 would block autophagy, this has not been pre-
viously shown and highlights the importance of ULK kinase
activity in autophagy induction. It also acts as a proof-of-prin-
ciple in developing small molecule inhibitors to block
autophagy for therapy in diseases such as cancer. Finally, we
have developed a system to enable molecular analysis of ULK1
function in autophagy and revealed a role for ULK1 in the mat-
uration of autophagosomes. Future work will hopefully identify
the targets of ULK1 that enable the phagophore to autophago-
some switch.
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